The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.
about
The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
The combination of anti-KIR mo ...... tumor immune escape in NSCLC.
@en
The combination of anti-KIR mo ...... tumor immune escape in NSCLC.
@nl
type
label
The combination of anti-KIR mo ...... tumor immune escape in NSCLC.
@en
The combination of anti-KIR mo ...... tumor immune escape in NSCLC.
@nl
prefLabel
The combination of anti-KIR mo ...... tumor immune escape in NSCLC.
@en
The combination of anti-KIR mo ...... tumor immune escape in NSCLC.
@nl
P2093
P2860
P356
P1476
The combination of anti-KIR mo ...... g tumor immune escape in NSCLC
@en
P2093
Caicun Zhou
Daniel Chan
Jane Mattei
Paul A Bunn
P2860
P304
P356
10.2147/DDDT.S163304
P407
P50
P577
2018-04-24T00:00:00Z